Separately, BMO Capital Markets reiterated a “buy” rating and set a $33.00 target price on shares of Scholar Rock in a research report on Monday, June 29th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Scholar Rock presently has an average rating of “Buy” and a consensus target price of $28.33.
Shares of SRRK opened at $18.17 on Friday. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.46 and a quick ratio of 4.46. Scholar Rock has a 1 year low of $6.95 and a 1 year high of $21.92. The company has a 50 day simple moving average of $14.27 and a two-hundred day simple moving average of $15.57. The firm has a market cap of $542.83 million, a P/E ratio of -8.37 and a beta of 0.79.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Meeder Asset Management Inc. bought a new stake in Scholar Rock in the first quarter worth $26,000. Bank of Montreal Can lifted its position in Scholar Rock by 11,300.0% in the second quarter. Bank of Montreal Can now owns 1,824 shares of the company’s stock worth $30,000 after buying an additional 1,808 shares during the last quarter. Ameritas Investment Partners Inc. lifted its position in Scholar Rock by 63.4% in the second quarter. Ameritas Investment Partners Inc. now owns 2,007 shares of the company’s stock worth $37,000 after buying an additional 779 shares during the last quarter. BNP Paribas Arbitrage SA lifted its position in Scholar Rock by 162.4% in the first quarter. BNP Paribas Arbitrage SA now owns 5,458 shares of the company’s stock worth $66,000 after buying an additional 3,378 shares during the last quarter. Finally, Citigroup Inc. lifted its position in Scholar Rock by 18.9% in the first quarter. Citigroup Inc. now owns 6,988 shares of the company’s stock worth $85,000 after buying an additional 1,113 shares during the last quarter. Hedge funds and other institutional investors own 66.27% of the company’s stock.
About Scholar Rock
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Its lead antibody product candidate is SRK-015, an inhibitor of the activation of myostatin, which is in Phase I clinical trials for the treatment of spinal muscular atrophy.
Read More: Secondary Public Offerings
Receive News & Ratings for Scholar Rock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scholar Rock and related companies with MarketBeat.com's FREE daily email newsletter.